Alpha Tau Medical's 2023 loss narrowed to $29.2 million, partly because of financial income, and its cash is expected to cover at least 2 years. Higher research and marketing spending adds costs, but the cash runway and advancing clinical work support the outlook.
The cash gives Alpha Tau time to keep testing its treatment and work toward selling it. The smaller loss partly came from financial income, and research and marketing costs rose. Still, continued clinical work and the expected cash runway make this update favorable.
Follow Alpha Tau Medical (DRTS) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for DRTS